sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit
Company profile
Ticker
SNSE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Sensei Biotherapeutics, Inc. Corporate Company ...
SNSE stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
12 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Feb 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7 Nov 23
Latest ownership filings
SC 13D/A
Newtyn Management, LLC
7 Mar 24
4
der Horst Edward van
16 Feb 24
4
John Celebi
16 Feb 24
4
Erin Colgan
16 Feb 24
SC 13D/A
Newtyn Management, LLC
13 Feb 24
SC 13D
Newtyn Management, LLC
3 Nov 23
4
Stephanie Krebs
2 Nov 23
3
Stephanie Krebs
2 Nov 23
4
John Celebi
13 Sep 23
4
Patrick Stephen Gallagher
11 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.34 mm | 11.34 mm | 11.34 mm | 11.34 mm | 11.34 mm | 11.34 mm |
Cash burn (monthly) | (no burn) | 8.92 k | 2.58 mm | 3.50 mm | 1.55 mm | 2.95 mm |
Cash used (since last report) | n/a | 61.42 k | 17.76 mm | 24.09 mm | 10.70 mm | 20.34 mm |
Cash remaining | n/a | 11.28 mm | -6.42 mm | -12.75 mm | 641.62 k | -9.00 mm |
Runway (months of cash) | n/a | 1265.2 | -2.5 | -3.6 | 0.4 | -3.0 |
Institutional ownership, Q3 2022
82.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 3 |
Closed positions | 15 |
Increased positions | 7 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 41.79 mm |
Total shares | 20.66 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cambrian BioPharma | 5.23 mm | $30.34 mm |
James Peyer | 4.69 mm | $0.00 |
H&S Investments I | 4.44 mm | $0.00 |
Apeiron Investment | 3.44 mm | $7.02 mm |
Ra Capital Management | 683.53 k | $1.06 mm |
Vanguard | 573.46 k | $889.00 k |
Newtyn Management | 415.00 k | $643.00 k |
Renaissance Technologies | 205.80 k | $319.00 k |
BLK Blackrock | 173.95 k | $270.00 k |
Bridgeway Capital Management | 162.90 k | $252.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | der Horst Edward van | Common Stock | Payment of exercise | Dispose F | No | No | 0.79 | 2,843 | 2.25 k | 56,070 |
15 Feb 24 | der Horst Edward van | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 90,102 | 71.18 k | 90,102 |
15 Feb 24 | der Horst Edward van | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 125,000 | 98.75 k | 125,000 |
15 Feb 24 | John Celebi | Common Stock | Payment of exercise | Dispose F | No | No | 0.79 | 5,891 | 4.65 k | 105,420 |
15 Feb 24 | John Celebi | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 165,889 | 131.05 k | 165,889 |
15 Feb 24 | John Celebi | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 315,000 | 248.85 k | 315,000 |
15 Feb 24 | Erin Colgan | Common Stock | Payment of exercise | Dispose F | No | No | 0.79 | 3,627 | 2.87 k | 67,462 |
15 Feb 24 | Erin Colgan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 94,128 | 74.36 k | 94,128 |
15 Feb 24 | Erin Colgan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.79 | 125,000 | 98.75 k | 125,000 |
1 Nov 23 | Stephanie Krebs | Stock Option Common Stock | Grant | Acquire A | No | No | 0.82 | 125,000 | 102.50 k | 125,000 |
News
Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting
24 Apr 24
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism Of Action Of SNS-101 Selectively Targeting The Active Form Of VISTA Within The Tumor Microenvironment
4 Apr 24
Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
28 Feb 24
Press releases
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
9 Apr 24
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
4 Apr 24
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
22 Mar 24
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
6 Mar 24
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Feb 24